LifeStance Health Group earnings release, May 7, 2026

LifeStance Health Group, Inc. (LFST) · Form 8-K, Item 2.02 · Filed · SEC filing

Investor Relations Contact

Monica Prokocki

VP of Finance & Investor Relations

602-767-2100 investor.relations@lifestance.com

LifeStance Reports First Quarter 2026 Results

SCOTTSDALE, Ariz. – May 7, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

2026 Highlights and FY 2026 Outlook

• Revenue of $403.5 million increased 21% compared to revenue of $333.0 million

• Clinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarter

• First quarter visit volumes increased 18% to 2.5 million

• Net income of $14.2 million compared to net income of $0.7 million

• Adjusted EBITDA of $51.1 million compared to Adjusted EBITDA of $34.6 million

• Net cash provided by operations of $33.1 million in the first quarter

• Free Cash Flow generation of $22.3 million in the first quarter

• For full year 2026, raising revenue expectations to $1.640 billion to $1.680 billion, Center Margin expectations to $547 million to $571 million, and Adjusted EBITDA of $200 million to $220 million

“We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance. “Our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare. We also took an important step forward in our commitment to clinical excellence by announcing an outcomes study on approximately 180,000 LifeStance patients that showed roughly three quarters reported clinically significant improvement in anxiety and depression.”

NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

• Revenue grew 21% to $403.5 million. Revenue growth in the first quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

• i ncome from operations was $22.3 million and net income was $14.2 million.

• Center Margin grew 24% to $135.9 million, or 33.7% of total revenue.

• Adjusted EBITDA increased 48% to $51.1 million, or 12.7% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the first quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the three months ended March 31, 2026, LifeStance generated $33.1 million cash flow from operations. The Company ended the first quarter with cash of $194.8 million and net long-term debt of $262.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

• The Company is raising full year revenue to $1.640 billion to $1.680 billion, Center Margin to $547 million to $571 million, and Adjusted EBITDA to $200 million to $220 million.

• For the second quarter of 2026, the Company expects total revenue of $405 million to $425 million, Center Margin of $135 million to $147 million, and Adjusted EBITDA of $50 million to $60 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, May 7, 2026 at 8:30 a.m. Eastern Time to discuss the first quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 8795477 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Financial statements

Income Statement (in millions)

Q1 2026Q1 2025Y/Y
(in millions)Total revenue403.533321.0%
(in millions)Income from operations22.31.6
(in millions)Center Margin135.9109.824.0%
(in millions)Net income14.20.7
(in millions)Adjusted EBITDA51.134.648.0%
As % of Total revenue:Income from operations5.50.5
As % of Total revenue:Center Margin33.733
As % of Total revenue:Net income3.50.2
As % of Total revenue:Adjusted EBITDA12.710.4

Income Statement

Three Months Ended March 31, — (In thousands, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
TOTAL REVENUE403,476332,970
OPERATING EXPENSESCenter costs, excluding depreciation and amortization shown separately below267,544223,179
OPERATING EXPENSESGeneral and administrative expenses100,33094,431
OPERATING EXPENSESDepreciation and amortization13,31813,756
OPERATING EXPENSESTotal operating expenses381,192331,366
OPERATING EXPENSESINCOME FROM OPERATIONS22,2841,604
OTHER EXPENSELoss on remeasurement of contingent consideration-5
OTHER EXPENSETransaction costs-544
OTHER EXPENSEInterest expense, net-1,793-3,073
OTHER EXPENSEOther expense-182-1
OTHER EXPENSETotal other expense-2,524-3,074
OTHER EXPENSEINCOME (LOSS) BEFORE INCOME TAXES19,760-1,470
OTHER EXPENSEINCOME TAX (PROVISION) BENEFIT-5,5172,179
OTHER EXPENSENET INCOME14,243709
EARNINGS PER SHAREBasic0.040
EARNINGS PER SHAREDiluted0.040
Weighted-average shares outstandingBasic387,264383,272
Weighted-average shares outstandingDiluted395,084390,666
Weighted-average shares outstandingNET INCOME14,243709
OTHER COMPREHENSIVE LOSSUnrealized losses on cash flow hedge, net of tax-317
OTHER COMPREHENSIVE LOSSCOMPREHENSIVE INCOME14,243392

Income Statement

Three Months Ended March 31, — FROM OPERATIONS TO CENTER MARGIN (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Income from operations22,2841,604
Adjusted for:Depreciation and amortization13,31813,756
Adjusted for:General and administrative expenses (1)100,33094,431
Adjusted for:Center Margin135,932109,791

Income Statement

Three Months Ended March 31, — TO ADJUSTED EBITDA (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income14,243709
Adjusted for:Interest expense, net1,7933,073
Adjusted for:Depreciation and amortization13,31813,756
Adjusted for:Income tax provision (benefit)5,517-2,179
Adjusted for:Loss on remeasurement of contingent consideration5
Adjusted for:Stock-based compensation expense15,20118,584
Adjusted for:Loss on disposal of assets1821
Adjusted for:Transaction costs (1)544
Adjusted for:Executive transition costs185
Adjusted for:Litigation costs (2)-197205
Adjusted for:Strategic initiatives (3)86
Adjusted for:Real estate optimization and restructuring charges (4)-45
Adjusted for:Amortization of cloud-based software implementation costs (5)418357
Adjusted for:Adjusted EBITDA51,11034,646

Balance Sheet

March 31, 2026 — (In thousands, except for par value)

March 31, 2026December 31, 2025
CURRENT ASSETSCash and cash equivalents194,797248,642
CURRENT ASSETSPatient accounts receivable, net122,91695,710
CURRENT ASSETSPrepaid expenses and other current assets38,19871,848
CURRENT ASSETSTotal current assets355,911416,200
NONCURRENT ASSETSProperty and equipment, net161,468161,583
NONCURRENT ASSETSRight-of-use assets151,526149,720
NONCURRENT ASSETSIntangible assets, net175,141177,665
NONCURRENT ASSETSGoodwill1,296,9991,293,346
NONCURRENT ASSETSOther noncurrent assets4,8375,419
NONCURRENT ASSETSTotal noncurrent assets1,789,9711,787,733
NONCURRENT ASSETSTotal assets2,145,8822,203,933
CURRENT LIABILITIESAccounts payable4,2926,122
CURRENT LIABILITIESAccrued payroll expenses117,306143,327
CURRENT LIABILITIESOther accrued expenses52,40842,187
CURRENT LIABILITIESOperating lease liabilities, current47,36945,544
CURRENT LIABILITIESOther current liabilities18,35714,782
CURRENT LIABILITIESTotal current liabilities239,732251,962
NONCURRENT LIABILITIESLong-term debt, net262,459265,927
NONCURRENT LIABILITIESOperating lease liabilities, noncurrent148,821148,553
NONCURRENT LIABILITIESDeferred tax liability, net16,40816,408
NONCURRENT LIABILITIESOther noncurrent liabilities1,04668
NONCURRENT LIABILITIESTotal noncurrent liabilities428,734430,956
NONCURRENT LIABILITIESTotal liabilities668,466682,918
STOCKHOLDERS’ EQUITYCommon stock – par value $0.01 per share; 800,000 shares authorized as of March 31, 2026 and December 31, 2025; 387,813 and 388,318 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively3,8783,883
STOCKHOLDERS’ EQUITYAdditional paid-in capital2,267,9212,325,758
STOCKHOLDERS’ EQUITYAccumulated deficit-794,383-808,626
STOCKHOLDERS’ EQUITYTotal stockholders' equity1,477,4161,521,015
STOCKHOLDERS’ EQUITYTotal liabilities and stockholders’ equity2,145,8822,203,933

Cash Flow

Three Months Ended March 31, — (In thousands) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet income14,243709
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation and amortization13,31813,756
Full release

Forward-Looking Statements... (truncated) results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by (used in) operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income or income from operations.

Center Margin and Adjusted EBITDA anticipated for the second quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking second quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

# # # #

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · LifeStance Health Group earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.